AU4070897A - Method for treating diabetes - Google Patents

Method for treating diabetes

Info

Publication number
AU4070897A
AU4070897A AU40708/97A AU4070897A AU4070897A AU 4070897 A AU4070897 A AU 4070897A AU 40708/97 A AU40708/97 A AU 40708/97A AU 4070897 A AU4070897 A AU 4070897A AU 4070897 A AU4070897 A AU 4070897A
Authority
AU
Australia
Prior art keywords
treating diabetes
diabetes
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40708/97A
Inventor
Kurt B. Osther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU4070897A publication Critical patent/AU4070897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU40708/97A 1996-08-16 1997-08-15 Method for treating diabetes Abandoned AU4070897A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69892696A 1996-08-16 1996-08-16
US08698926 1996-08-16
US76029996A 1996-12-04 1996-12-04
US08760299 1996-12-04
PCT/US1997/014448 WO1998006431A2 (en) 1996-08-16 1997-08-15 Method for treating diabetes

Publications (1)

Publication Number Publication Date
AU4070897A true AU4070897A (en) 1998-03-06

Family

ID=27106305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40708/97A Abandoned AU4070897A (en) 1996-08-16 1997-08-15 Method for treating diabetes

Country Status (3)

Country Link
EP (1) EP0859633A2 (en)
AU (1) AU4070897A (en)
WO (1) WO1998006431A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
MX2007009466A (en) 2005-02-10 2007-12-07 Baylor Res Inst Anti-interferon alpha monoclonal antibodies and methods for use.
WO2009135861A2 (en) 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
US20140242038A1 (en) * 2011-10-11 2014-08-28 The Trustees Of Columbia University In The City Of New York Method for generating beta cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3005897A1 (en) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt GENERAL PRODUCT OF A HIGHER ORGANISM FROM A MICROORGANISM CONTAINING THIS GENE
WO1993004699A1 (en) * 1991-08-30 1993-03-18 Genentech, Inc. Therapeutic method for iddm
IL106591A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
EP0823941A4 (en) * 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice

Also Published As

Publication number Publication date
WO1998006431A3 (en) 1998-06-18
WO1998006431A2 (en) 1998-02-19
EP0859633A2 (en) 1998-08-26

Similar Documents

Publication Publication Date Title
AU6479596A (en) Methods for treating diabetes
AU2543097A (en) Method for treating pain
AU2587297A (en) Method for treating pain
AU9035498A (en) Method for treating pain
AU3813397A (en) Apparatus for treating chondromalicia
AU2326297A (en) Method for treating liquid materials
AU3896495A (en) Combination method for acne treatment
AU6589798A (en) Ileus treatment method
AU9423798A (en) Method for treating cellulosic shaped bodies
AU2808997A (en) Method for treating inflammation
AU2936897A (en) Subchirp processing method
AU1074397A (en) Method for treating anxiety
AU5317398A (en) Method for preparing cyclopropylamines
AU5362598A (en) Method for improving wastewater treatment
AU2340897A (en) Method for treating pain
AU4046797A (en) Method for treating mental retardation
AU7107998A (en) Method for treating schizophrenia
AU2183997A (en) New method
AU7726396A (en) Method for treating anxiety
AU8920798A (en) Method for treating neuropathic pain
AU3704297A (en) Method
AU6688798A (en) Method for treating lumber
AU9034798A (en) Method for treating pain
AU6760298A (en) Method for treating hypertension
AU3746397A (en) Tempering method